Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Immuno-Oncology Data Drive Deal Dollars Higher

Executive Summary

Immuno-oncology deals command relatively high values, but transaction volumes are increasing annually at a steady pace, not skyrocketing despite intense interest in the field as big pharma companies remain selective IO dealmakers based on the strength of early-stage data.

Advertisement

Related Content

Stockwatch: Fireworks Or Ballistic Missiles In Biotechnology?
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump
INFOGRAPHIC: A US biotech IPO surge? Data are mixed
Aduro gets $200m as Novartis steps up immuno-oncology
NewLink-Genentech deal could be worth more than $1bn
Janssen signs $847m lung cancer immunotherapy deal with Aduro
Janssen gains immunotherapies, boosts prostate portfolio with Aduro deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel